SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.885
+0.085 (2.24%)
Jun 29, 2026, 3:10 PM EDT - Market open
SAB Biotherapeutics Employees
SAB Biotherapeutics had 86 employees as of December 31, 2025. The number of employees increased by 23 or 36.51% compared to the previous year.
Employees
86
Change (1Y)
23
Growth (1Y)
36.51%
Revenue / Employee
n/a
Profits / Employee
-$109,428
Market Cap
297.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Entrada Therapeutics | 152 |
| Adagene | 128 |
| Zentalis Pharmaceuticals | 106 |
| Neumora Therapeutics | 92 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Surrozen | 44 |
SABS News
- 5 days ago - SAB Biotherapeutics initiated with an Overweight at Barclays - TheFly
- 4 weeks ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Citi - TheFly
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Jefferies - TheFly
- 6 weeks ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 6 weeks ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - SAB Biotherapeutics Earnings release: Q1 2026 - Filings